ArticleAging cell2025
Temporal Changes in Alzheimer's Disease-Related Biomarkers in the CSF of Cognitively Normal Subjects at Different Ages: The Chongqing Ageing and Dementia Study.
Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Alzheimer's disease progression with YKL40 levels in peripheral blood and cerebrospinal fluid: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Prognostic Value of CSF Total Tau Protein in Patients with Familial and Sporadic Creutzfeldt-Jakob Disease.Dementia and geriatric cognitive disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Revealing the temporal evolution of cerebrospinal fluid (CSF) biomarkers during aging is critical to understanding disease pathogenesis and developing early diagnoses and interventions for Alzheimer's disease (AD). CSF was obtained from 549 cognitively normal subjects between 18 and 93 years of age. 12 AD-related biomarkers were evaluated, including amyloid β (Aβ42, Aβ40, Aβ42/Aβ40 ratio), hyperphosphorylated tau (P-tau), neuronal injury/degeneration (T-tau, NFL, NSE, H-FABP, VILIP-1), neuroinflammation biomarkers (YKL-40, TREM2), and α-synuclein (α-synuclein). Associations between these biomarkers and age as well as apolipoprotein E (APOE) ε4 status were evaluated, and the associations among biomarkers were assessed. CSF Aβ42, P-tau, and T-tau levels exhibited nonlinear associations with age, among which Aβ42 was significantly modulated by APOE ε4 status. Specifically, an accelerated decline in Aβ42 levels occurred at 45.69 years of age in the APOE ε4+ group, which was almost 23 years earlier than that in the APOE ε4- group (68.02 years). The age-related change pattern of CSF P-tau is similar to that of T-tau, with both increasing slightly with age but showing an accelerated change at ≈60 years of age in the APOE ε4+ group. All the other biomarkers except for α-synuclein were linearly associated with age, and APOE ε4 status had no effect on these associations. Most biomarkers were positively correlated with each other except for Aβ42/Aβ40 ratio. The evolution of AD-related biomarkers in CSF varies throughout the adult lifespan, with the APOE ε4 allele modifying the temporal changes in CSF Aβ42 levels, as well as potentially influencing P-tau and T-tau levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.